Homology Medicines Overview
- Founded
-
2015

- Status
-
Public
- Employees
-
104

- Stock Symbol
-
FIXX

- Investments
-
1
- Share Price
-
$2.89
- (As of Monday Closing)
Homology Medicines General Information
Description
Homology Medicines Inc is a US-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Contact Information
Website
www.homologymedicines.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- One Patriots Park
- Bedford, MA 01730
- United States
Homology Medicines Stock Performance
(As of Monday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$2.89 | $2.76 | $1.30 - $8.90 | $158M | 57.4M | 369K | -$0.06 |
Homology Medicines Financials Summary
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 42,512 | 34,017 | 405,519 | 641,845 |
Revenue | 5,468 | 33,971 | 2,702 | 1,666 |
EBITDA | 5,414 | (87,596) | (122,298) | (103,625) |
Net Income | (2,586) | (95,764) | (128,694) | (103,916) |
Total Assets | 310,958 | 211,721 | 263,737 | 310,567 |
Total Debt | 23,983 | 23,934 | 15,442 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Homology Medicines Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Homology Medicines Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Homology Medicines Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Homology Medicines Inc is a US-based genetic medicines company dedicated to transforming the lives of patients suffering
Biotechnology
Bedford, MA
104
As of 2021
00000
0000
0000-00-00
000000000
00000
Homology Medicines Competitors (78)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Audentes Therapeutics | Formerly VC-backed | San Francisco, CA | 000 | 00000 | 000000&0 | 00000 |
0000 000000 | Formerly VC-backed | San Diego, CA | 00 | 00000 | 00000000 | 00000 |
000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
000000000 | Formerly VC-backed | Tucson, AZ | 00 | 000.00 | 000000&0 | 000.00 |
0000 00000000000 | Formerly VC-backed | Redwood City, CA | 00 | 00000 | 000000&0 | 00000 |
Homology Medicines Patents
Homology Medicines Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20220160728-A1 | Gene therapy methods | Pending | 05-Nov-2020 | 0000000000 | |
US-20220106611-A1 | Vectorized antibodies and uses thereof | Pending | 09-Sep-2020 | 000000000 | |
US-20210393804-A1 | Adeno-associated virus compositions for restoring pah gene function and methods of use thereof | Pending | 27-May-2020 | 0000000000 | |
US-20210361778-A1 | Adeno-associated virus compositions for ids gene transfer and methods of use thereof | Pending | 06-Apr-2020 | 000000000 | |
US-20210261983-A1 | Methods of treating phenylketonuria | Pending | 13-Jan-2020 | A61K48/005 |
Homology Medicines Executive Team (16)
Homology Medicines Board Members (14)
Name | Representing | Role | Since |
---|---|---|---|
Alise Reicin MD | Self | Board Member | 000 0000 |
Arthur Tzianabos Ph.D | Homology Medicines | President, Chief Executive Officer & Board Member | 000 0000 |
Cameron Wheeler Ph.D | Self | Board Member | 000 0000 |
Jason Ruth Ph.D | 5AM Ventures | Board Observer | 000 0000 |
Jeffrey Poulton | Self | Board Member | 000 0000 |
Homology Medicines Signals
Homology Medicines Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Homology Medicines Investments (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000000 000000 | 10-Mar-2022 | 00000 0000 | 0000 | Drug Discovery | 000000 00 |